Farxiga Side Effects: Common, Rare, and Serious

Farxiga (dapagliflozin) causes your kidneys to flush excess glucose into your urine, and most of its side effects trace directly back to that sugar-rich urine and the fluid loss that comes with it. The most frequent complaints are genital yeast infections and urinary tract infections, while the rarest but most dangerous risks include a form of diabetic ketoacidosis that can fool both patients and doctors because blood sugar stays near normal. Understanding which side effects are merely annoying and which demand emergency attention makes a real difference in how safely you can use this drug.

How the Drug Works and Why That Matters for Side Effects

Farxiga belongs to a class of medications called SGLT2 inhibitors. In a healthy kidney, a protein called SGLT2 reabsorbs most of the glucose that gets filtered out of your blood, sending it back into circulation. Farxiga blocks that protein, cutting glucose reabsorption by roughly half to sixty percent.¹ The glucose that doesn’t get reabsorbed ends up in your urine instead.

This mechanism is elegant in some ways. Because Farxiga works by dumping sugar rather than forcing your pancreas to produce more insulin, the risk of dangerously low blood sugar is low. The drug essentially stops working once your blood sugar drops below the threshold where glucose spills into urine, which acts as a built-in safety brake.² But the same mechanism that makes the drug effective also creates a warm, sugar-laden environment in your urinary tract, and pulls extra water along with the glucose. Nearly every common side effect flows from one of those two consequences.

Genital Fungal Infections

The single most talked-about side effect of Farxiga is genital yeast infections, and for good reason. Yeast thrives on sugar. When glucose constantly passes through your urinary and genital tract, you’re essentially creating ideal growing conditions for Candida. Across large observational studies, genital mycotic infections were consistently elevated in people taking SGLT2 inhibitors, with hazard ratios roughly two to three times higher than in people on other diabetes medications.¹³

Women are affected more often than men, though men are not exempt. In women, symptoms typically show up as vaginal itching, discharge, and irritation. In men, the infection usually appears on the head of the penis, especially in uncircumcised men. These infections are generally mild to moderate and respond well to standard antifungal treatments, but they can be recurrent. For some people, repeated yeast infections become the main reason they stop taking Farxiga.

Good hygiene practices help reduce risk. Keeping the genital area dry, wearing breathable cotton underwear, and treating infections promptly rather than waiting all make a difference. Your doctor may also prescribe a preventive antifungal if infections keep coming back.

Urinary Tract Infections

Urinary tract infections get a lot of attention in conversations about Farxiga, but the actual risk increase is more modest than many people expect. A large systematic review of observational studies found that SGLT2 inhibitors were not clearly associated with a higher rate of UTIs compared to other diabetes treatments, with hazard ratios hovering close to or below 1.0.⁴ That said, reviews of clinical trial data have noted a modest link, particularly when compared to placebo.³

A smaller descriptive study specifically looking at dapagliflozin users found that the large majority of patients did not develop UTIs at all, and those who did experienced infections that were predominantly mild to moderate.⁵ The practical takeaway is that UTIs are worth watching for but shouldn’t scare you away from the medication. Staying well hydrated, urinating regularly, and not holding it in for long stretches all help.

Increased Urination and Thirst

Because Farxiga dumps glucose into your urine and water follows along, you will likely urinate more often and in greater volume, particularly in the first few weeks. This is the drug doing what it’s supposed to do. Most people adjust within a month or two as their bodies reach a new equilibrium, but in the early days you might feel like you’re constantly looking for a bathroom.

The extra fluid loss also means you may feel thirstier than usual. Drinking enough water matters here. If you’re not replacing the fluid you’re losing, you can become dehydrated, which leads to dizziness on standing, lightheadedness, or feeling faint. Older adults and people already taking diuretics (water pills) for blood pressure or heart failure are at the highest risk for this kind of volume depletion. If you notice persistent dizziness when you stand up quickly, mention it to your doctor because your other medications or fluid intake may need adjusting.

What Happens to Your Kidney Numbers

When you first start Farxiga, your doctor will likely check your kidney function, and the number they’re looking at is your estimated glomerular filtration rate, or eGFR. It’s common to see that number dip in the first month or two. In the DAPA-HF trial of heart failure patients, the average decline was around 3 points (about 5%), and roughly a third of patients experienced a drop of more than 10%.⁶ A similar early dip has been documented in chronic kidney disease patients without diabetes as well.⁷

This sounds alarming, but the dip is actually considered a sign that the drug is working. Farxiga changes the pressure dynamics inside the kidney in a way that is protective over the long term, even though the short-term eGFR reading looks worse. The initial dip typically stabilizes after a couple of months. The key question is whether the decline is the expected hemodynamic effect or a sign of actual kidney damage, and that’s something your doctor assesses by watching whether the number stabilizes or keeps falling. If it keeps dropping significantly beyond those first few months, that warrants further investigation.

Weight Loss and Body Composition

Many people taking Farxiga notice weight loss, and it’s not a coincidence. When you’re flushing glucose out through your urine, you’re literally excreting calories your body would otherwise have stored. This typically translates to a modest but real drop in body weight.

The encouraging part is where that weight comes from. A six-month study using body composition analysis found that dapagliflozin significantly reduced total fat mass and body fat percentage without meaningfully affecting skeletal muscle mass.⁸ That matters because many weight-loss approaches, including simple caloric restriction, can lead to loss of both fat and muscle. The fact that Farxiga appears to preferentially strip fat while sparing muscle is a meaningful benefit, especially for people with type 2 diabetes who already tend to lose muscle mass as they age.

The weight loss isn’t dramatic in most cases. Expect a few kilograms over months rather than a rapid transformation. Some of the initial drop is water weight from the increased urination. Over time, the body partially compensates by increasing appetite, which is why the weight loss tends to plateau rather than continue indefinitely.

Euglycemic Diabetic Ketoacidosis

This is the side effect that genuinely keeps endocrinologists up at night. Diabetic ketoacidosis is a dangerous condition where the body starts breaking down fat at an uncontrolled rate, producing acids called ketones that make the blood dangerously acidic. Normally, DKA comes with sky-high blood sugar, which makes it easy to recognize. But Farxiga can trigger a version where blood sugar stays below 200 mg/dL, sometimes even in the normal range.⁹

The danger here is diagnostic delay. A patient shows up with nausea, vomiting, abdominal pain, and feeling generally terrible, but their blood sugar looks fine, so neither they nor sometimes even their emergency room team immediately thinks “ketoacidosis.” By the time someone checks ketone levels or blood gas values, the situation may have progressed. Multiple case reports and case series have documented this association with SGLT2 inhibitors.¹⁰

Certain situations dramatically raise the risk. Illness, surgery, prolonged fasting, very low-carb diets, excessive alcohol intake, and dehydration can all tip the balance toward ketoacidosis in someone taking Farxiga. The warning signs to watch for include:

Nausea or vomiting: especially if persistent and not explained by something obvious like food poisoning
Abdominal pain: often diffuse and accompanied by loss of appetite
Unusual fatigue: feeling profoundly weak or confused beyond what a normal sick day would explain
Rapid or deep breathing: your body trying to blow off the excess acid

If you experience these symptoms, checking your blood sugar and finding it normal does not rule out ketoacidosis. Ask for a ketone check, either a blood test for beta-hydroxybutyrate or a urine ketone strip. Make sure any emergency physician treating you knows you take an SGLT2 inhibitor.

Stopping Farxiga Before Surgery

The euglycemic DKA risk is why most surgical teams now require patients to stop Farxiga several days before any planned procedure. The stress of surgery, combined with fasting and the lingering effects of the drug, creates a perfect storm for ketoacidosis. A study of over 500 open heart surgery patients found that when SGLT2 inhibitor users were told to stop the medication five days before their procedure, none developed euglycemic DKA in the immediate postoperative period.¹¹

Most current guidance suggests stopping Farxiga at least three to five days before major surgery. Some anesthesiologists are more conservative and recommend stopping it even earlier for cardiac operations. If you’re scheduling any procedure requiring anesthesia, bring up the topic proactively with both your prescribing doctor and the surgical team. It’s the kind of detail that can fall through the cracks during pre-op planning.

Fournier’s Gangrene

This is rare but terrifying. Fournier’s gangrene is a rapidly spreading, life-threatening infection of the tissue in the genital and perianal area. The FDA issued a warning about a connection between SGLT2 inhibitors and this condition after reviewing post-marketing reports.¹² A pharmacovigilance analysis of the FDA’s adverse event reporting system identified 542 cases of Fournier’s gangrene across all SGLT2 inhibitors, with about 72% of those patients requiring hospitalization and roughly 5% dying.¹³

To put those numbers in context, hundreds of millions of SGLT2 inhibitor prescriptions have been written worldwide, so 542 reported cases makes this exceedingly rare. But the severity is extreme. Fournier’s gangrene requires emergency surgery to remove dead tissue, intravenous antibiotics, and often a prolonged hospital stay. The link to Farxiga makes biological sense: sugar-rich urine encourages infections, and any untreated genital or urinary infection can theoretically progress to necrotizing fasciitis in vulnerable individuals, particularly those who are older, have diabetes (which already impairs wound healing), or are immunocompromised.

The practical message is simple: don’t ignore any unusual redness, swelling, warmth, or tenderness in the genital or perianal area, especially if accompanied by fever. Seek medical attention the same day. Early intervention is the difference between an infection that gets treated with antibiotics and one that requires surgery.

Other Signals From Safety Databases

Post-marketing surveillance databases have turned up a few additional signals worth knowing about. A recent pharmacovigilance study covering SGLT2 inhibitor reports from 2013 through 2024 identified cellulitis, acute pancreatitis, and necrotizing pancreatitis as unexpected adverse event signals.¹⁴ “Unexpected” here means these were not initially anticipated based on the drug’s mechanism.

There has also been discussion about whether SGLT2 inhibitors increase the risk of lower limb amputations, a concern that originally surfaced with canagliflozin (Invokana), a different drug in the same class. For SGLT2 inhibitors as a group, the data on amputations is mixed and uncertain, with some studies showing elevated risk and others not. A systematic review of population-based studies found the range of hazard ratios for amputation was wide enough to make it hard to draw firm conclusions.⁴ The same review found no clear increase in fracture risk or acute kidney injury with SGLT2 inhibitor use.

Potassium and Electrolyte Changes

Because Farxiga affects how the kidneys handle fluid, you might wonder whether it throws off your electrolytes. The answer, at least for potassium, is reassuring. A pooled analysis of clinical trial data found no clinically meaningful change in average serum potassium with dapagliflozin compared to placebo. Slightly more patients on dapagliflozin had low potassium readings (around 5% versus about 4% on placebo), but no one dropped to dangerously low levels. And there was no increased risk of high potassium even in patients who were simultaneously taking medications known to raise potassium levels, like ACE inhibitors or potassium-sparing diuretics.¹⁵

This is particularly relevant for people with heart failure or kidney disease, who often take multiple medications that affect potassium balance. The fact that Farxiga doesn’t meaningfully disturb potassium levels is one reason it has been adopted so widely in those populations. Your doctor will still check your labs periodically, but potassium derangement is not a major concern with this drug.

Does the Side Effect Profile Change in Non-Diabetic Patients

Farxiga is now prescribed for heart failure and chronic kidney disease regardless of whether a patient has diabetes. That raises a reasonable question: do you still get the same side effects if your blood sugar is normal to begin with?

The short answer is that most side effects are milder in non-diabetic patients, particularly the genital infections and the eGFR dip. Without the chronically elevated blood sugar of diabetes, there is less glucose in the urine to feed yeast or bacteria. The drug still causes some glucosuria in people with normal blood sugar, but the amount is smaller because there’s less glucose being filtered in the first place. The built-in safety brake described earlier also means the drug produces less glucose in the urine as blood sugar levels decline, which limits both the caloric loss and the infection risk.²

The euglycemic DKA risk is largely confined to people with diabetes, particularly type 1 diabetes (where Farxiga is generally not approved) and type 2 diabetes in situations of metabolic stress. It’s theoretically possible in a non-diabetic patient under extreme circumstances, but exceedingly rare. Heart failure trials in non-diabetic patients have shown the cardiovascular and kidney benefits to be similar to those in diabetic patients, with the side effect burden if anything slightly lighter.¹⁶

When to Call Your Doctor Versus When to Go to the ER

Not all side effects require the same urgency. Sorting them into the right bucket matters:

Schedule a routine appointment: recurring yeast infections, mild increases in urination, modest weight loss, or a minor drop in eGFR at your first lab check. These are worth discussing but not emergencies.
Call your doctor within a day: signs of a urinary tract infection (burning with urination, cloudy or strong-smelling urine, low-grade fever), persistent dizziness when standing, or unusual fatigue that doesn’t resolve with rest and hydration.
Go to the emergency room: severe nausea and vomiting that won’t stop, confusion, rapid or labored breathing, fever with redness and swelling in the genital area, or any sign of a serious infection spreading. These could indicate euglycemic DKA or Fournier’s gangrene, both of which require immediate treatment. Tell the ER team you take an SGLT2 inhibitor.

One practical tip worth mentioning: if you own a blood ketone meter (or even urine ketone strips, which are available over the counter), keeping one at home is a reasonable precaution when you’re on Farxiga. If you ever feel unusually sick and your blood sugar looks fine, a quick ketone check can give you early information that would otherwise only come from a blood draw at the hospital.

1
PubMed Central. SGLT2 Inhibitors: Physiology and Pharmacology
2
PubMed Central. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
3
PubMed. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes
4
SpringerLink (Diabetes Therapy). Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) Exposure and Outcomes in Type 2 Diabetes: A Systematic Review of Population-Based Observational Studies
5
Alqalam Journal of Medical and Applied Sciences. Incidence and Risk Factors of Urinary Tract Infection in Patients with Diabetes Mellitus Using Dapagliflozin in Benghazi, Libya
6
PubMed Central. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
7
PubMed Central. Effect of dapagliflozin on the initial estimated glomerular filtration rate dip in chronic kidney disease patients without diabetes mellitus
8
PubMed Central. Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes
9
BMJ. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
10
PubMed Central. “The Bitter Truth of Sugar”-Euglycemic Diabetic Ketoacidosis due to Sodium-glucose Cotransporter-2 Inhibitors: A Case Series
11
PubMed. Retrospective Chart Review of Euglycemic Diabetic Ketoacidosis Rates and Outcomes Postimplementation of Sodium Glucose Cotransporter 2 Inhibitor Use Stoppage 5 Days Before Open Heart Surgery
12
PubMed Central. Fournier’s gangrene with dapagliflozin in a rural hospital: a case report
13
PubMed Central. Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
14
PubMed. Serious adverse events reported with sodium-glucose cotransporter-2 (SGLT2) inhibitors in the FAERS database (2013-2024): a pharmacovigilance study
15
PubMed Central. Effect of the SGLT2 Inhibitor Dapagliflozin on Potassium Levels in Patients with Type 2 Diabetes Mellitus: A Pooled Analysis
16
SpringerLink / Netherlands Heart Journal. The effects of antidiabetic agents on heart failure